Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy

Clinical Research in Cardiology

Volumn 105, Issue 12, 2016, Pages 1011-1020

  Escher, Felicitas ^a,b,f   Kühl, Uwe ^a,b   Lassner, Dirk ^a   Poller, Wolfgang ^b,f   Westermann, Dirk ^c   Pieske, Burkert ^b,d,f   Tschöpe, Carsten ^b,e,f   Schultheiss, Heinz Peter ^a,b  

^a Institute for Cardiac Diagnostic and Therapy (IKDT)   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e Berlin Brandenburg Center of Regenerative Therapies (BCRT)   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Endomyocardial biopsy; Immunosuppressive therapy; Inflammatory cardiomyopathy; Intramyocardial inflammation; Long term follow up

Indexed keywords

AZATHIOPRINE; PREDNISONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; NONHUMAN; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; BIOPSY; CARDIOMYOPATHIES; CONVALESCENCE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; IMMUNOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME FACTOR;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BIOPSY; CARDIOMYOPATHIES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDITIS; PREDNISONE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84975113047     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-016-1011-z     Document Type: Article

References (38)

1. Cooper LT Jr (2009) Myocarditis. N Engl J Med 360:1526–1538
2. Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343:1388–1398
3. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648
4. Richardson P, McKenna W, Bristow M (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842
5. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2):270–276
6. Liu PP, Mason JW (2001) Advances in the understanding of myocarditis. Circulation 104:1076–1082
7. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648
8. Pankuweit S, Portig I, Maisch B (2002) Pathophysiology of cardiac inflammation: molecular mechanisms. Herz 27:669–676
9. Schultheiss HP, Kühl U, Cooper LT (2011) The management of myocarditis. Eur Heart J 32:2616–2625
10. Bowles NE, Javier FGF, Makar KA (2002) Analysis of the coxsackievirus B-adenovirus receptor gene in patients with myocarditis or dilated cardiomyopathy. Mol Genet Metab 77(3):257–259
11. Pauschinger M, Noutsias M, Lassner D, Schultheiss HP, Kuehl U (2006) Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis? Clin Res Cardiol 95(11):569–583
12. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, Siedentop H, Kuehl U (2016) Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. doi:10.1007/s00392-016-0986-9
13. Weitsman T, Weisz G, Keren A, Hasin T (2016) Prompt benefit of early immunosuppressive therapy in acute lymphocytic myocarditis with persistent heart failure. Clin Res Cardiol. doi:10.1007/s00392-016-0985-x
14. Frustaci A, Chimenti C, Pieroni M (2006) Cell death, proliferation and repair in human myocarditis responding to immunosuppressive therapy. Mod Pathol 19:755–765
15. Parrillo JE, Cunnion RE, Epstein SE (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061–1068
16. Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995–2002
17. Frustaci A, Chimenti C (2014) Immunosuppressive therapy in myocarditis. Circ J 79(1):4–7
18. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R, American Heart Association, American College of Cardiology, European Society of Cardiology, Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50(19):1914–1931
19. Escher F, Lassner D, Kühl U, Gross U, Westermann D, Poller W, Skurk C, Weitmann K, Hoffmann W, Tschöpe C, Schultheiss HP (2014) Analysis of endomyocardial biopsies in suspected myocarditis-diagnostic value of left versus right ventricular biopsy. Int J Cardiol 177(1):76–78
20. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111(7):887–893
21. Bock CT, Klingel K, Kandolf R (2010) Human parvovirus B19-associated myocarditis. N Engl J Med 362:1248–1249
22. Aretz HT (1987) Myocarditis: the Dallas criteria. Hum Pathol 18(6):619–624
23. Zuern CS, Walker B, Sauter M, Schaub M, Chatterjee M, Mueller K, Rath D, Vogel S, Tegtmeyer R, Seizer P, Geisler T, Kandolf R, Lang F, Klingel K, Gawaz M, Borst O (2015) Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. Clin Res Cardiol 104(12):1033–1043
24. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME (1995) A clinical trial of immunosuppressive therapy for myocarditis: The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269–275
25. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107:857–863
26. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C (2001) Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104:39–45
27. Cihakova D, Rose NR (2008) Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 99:95–114
28. Bulut D, Scheeler M, Niedballa LM, Miebach T, Mügge A (2011) Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 100(7):603–610
29. Kallwellis-Opara A, Dörner A, Poller WC, Noutsias M, Kühl U, Schultheiss HP, Pauschinger M (2007) Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol 96(7):469–480
30. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J (1997) Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 18(3):470–479
31. Noutsias M, Pauschinger M, Schultheiss HP, Kühl U (2003) Cytotoxic perforin-positive and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy. Eur J Heart Fail 5:469–479
32. Badorff C, Noutsias M, Kühl U, Schultheiss HP (1997) Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 29:429–434
33. Young LH, Joag SV, Zheng LM, Lee CP, Lee YS, Young JD (1990) Perforin-mediated myocardial damage in acute myocarditis. Lancet 336:1019–1021
34. Camina-Tato M, Morcillo-Suarez C, Bustamante MF et al (2010) Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol 185:5392–5404
35. Thomas HE, Trapani JA, Kay TW (2010) The role of perforin and granzymes in diabetes. Cell Death Differ 17:577–585
36. Pandya JM, Venalis P, Al-Khalili L, Hossain MS, Stache V, Lundberg IE, Malmström V, Fasth AE (2016) CD4+ and CD8+ CD28null T cells are cytotoxic to autologous muscle cells in polymyositis patients. Arthritis Rheumatol. doi:10.1002/art.39650
37. Escher F, Kühl U, Lassner D, Stroux A, Westermann D, Skurk C, Tschöpe C, Poller W, Schultheiss HP (2014) Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. Eur J Heart Fail 16(10):1066–1072
38. Yang JJ, Ye Y, Carroll A, Yang W, Lee HW (2001) Structural biology of the cell adhesion protein CD2: alternatively folded states and structure-function relation. Curr Protein Pept Sci 2(1):1–17